Evidence map›Paper›PMID 25496724›Full record

ArticleNeuropharmacology2015

Stereochemistry and neuropharmacology of a 'bath salt' cathinone: S-enantiomer of mephedrone reduces cocaine-induced reward and withdrawal in invertebrates.

Alexandre Vouga, Ryan A Gregg, Maryah Haidery, Anita Ramnath, Hassan K Al-Hassani, Christopher S Tallarida, David Grizzanti, Robert B Raffa, Garry R Smith, Allen B Reitz and 1 more

Open access · greenAbstract read
In one paragraph

Article in Neuropharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Alexandre VougaCenter for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA, USA; Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA, USA.
Ryan A GreggCenter for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA, USA; Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA, USA.
Maryah HaideryDepartment of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA, USA.
Anita RamnathDepartment of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA, USA.
Hassan K Al-HassaniDepartment of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA, USA.
Christopher S TallaridaCenter for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA, USA; Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA, USA.
David GrizzantiCenter for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA, USA; Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA, USA.
Robert B RaffaDepartment of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA, USA.
Garry R SmithFox Chase Chemical Diversity Center Inc., Doylestown, PA, USA.
Allen B ReitzFox Chase Chemical Diversity Center Inc., Doylestown, PA, USA.
Scott M RawlsCenter for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA, USA; Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA, USA. Electronic address: scott.rawls@temple.edu.
Temple University · USFox Chase Chemical Diversity Center · US

Funding

Pilot Projects Core (PPC)P30DA013429 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI Anjali M Rajadhyaksha · 2000 to 2026
$34.6M
Mephedrone and addiction: clues from animal modelsR21DA032718 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI RAWLS, SCOTT M. · 2012 to 2013
$337k
NIDA NIH HHS DA013429NIDA NIH HHS DA032718NIDA NIH HHS P30 DA013429NIDA NIH HHS R21 DA032718
6 · The paper itself

Abstract

Knowledge about the neuropharmacology of mephedrone (MEPH) applies primarily to the racemate, or street form of the drug, but not to its individual enantiomers. Here, through chemical isolation of MEPH enantiomers and subsequent behavioral characterization in established invertebrate (planarian) assays, we began separating adverse effects of MEPH from potential therapeutic actions. We first compared stereotypical and environmental place conditioning (EPC) effects of racemic MEPH, S-MEPH, and R-MEPH. Stereotypy was enhanced by acute treatment (100-1000 μM) with each compound; however, S-MEPH was less potent and efficacious than racemate and R-MEPH. Both R-MEPH (10, 100, 250 μM) and racemate (100 μM) produced EPC, but S-MEPH was ineffective at all concentrations (10-100 μM). After showing that S-MEPH lacked rewarding efficacy, we investigated its ability to alter three of cocaine's behavioral effects (EPC, withdrawal, and stereotypy). Cocaine (1 μM) produced EPC that was abolished when S-MEPH (100 μM) was administered after cocaine conditioning. Spontaneous withdrawal from chronic cocaine exposure caused a reduction in motility that was not evident during acute or continuous cocaine treatment but was attenuated by S-MEPH (100 μM) treatment during the cocaine abstinence interval. Acute stereotypy produced by 1 mM cocaine, nicotine or racemic MEPH was not affected by S-MEPH (10-250 μM). The present results obtained using planarian assays suggest that the R-enantiomer of MEPH is predominantly responsible for its stimulant and rewarding effects and the S-enantiomer is capable of antagonizing cocaine's addictive-like behaviors without producing rewarding effects of its own.

Indexed as

AnimalsCocaineConditioning, PsychologicalMethamphetamineMovementPlanariansRewardStereotyped BehaviorSubstance Withdrawal SyndromeCocainemephedroneMethamphetamineAddictionBath saltCathinoneCocaineConditioned place preferenceEnantiomerMephedronePlanariansStereochemistryStereotypyWithdrawal

Identifiers

PMID25496724
PMCPMC4418799
OpenAlexW2158821614

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.